Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
9 evidence topics · 14 sources
Summary: anticipated place in therapy
Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.
Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.
The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.
Proposed indication named in the pre-NDA announcement
Population studied in the phase 3 induction trials
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obefazimod (Obe), an oral, once‐daily (QD), small molecule which enhances expression of microRNA‐124 was studied in patients (pts) with moderately to severely active ulcerative colitis (UC) in Phase 2 studies [1–3].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer positioning as an oral advanced therapy
Manufacturer estimate of patients on conventional therapy
Analyst view on positioning against Janus kinase inhibitors
Guideline sequencing: early advanced therapy and absence of a hierarchy
“In adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies with or without immunomodulator therapy, rather than gradual step up after failure of 5-aminosalicylates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A summary of recommendations from the 2025 BSG IBD guidelines regarding the use of advanced therapies for induction and maintenance of remission in patients with moderate to severe IBD. Medications are not listed hierarchically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote